|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ocrelizumab for primary progressive multiple sclerosis显示文摘 | Montalban X Hauser SL Kappos L | 2017 | 中华物理医学与康复杂志2017，39，3： | 2 |
| 2 | Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis显示文摘 | Miller D Barkhof F Montalban X | 2005 | Lancet Neurol2005，4，5： | 1 |
| 3 | Clinically isolated syndromes suggestive of multiple sclerosis,part I:natural history,pathogenesis,di agnosis,and prognosis显示文摘 | Miller D Barkhof F Montalban X et a1 | 2005 | Lancet Neurol2005，4，11： | 1 |
| 4 | The value of animal models for drug development in multiple sclerosis显示文摘 | Friese MA Montalban X Willcox N | 2006 | Brain2006，129，8： | 1 |
| 5 | Clinically isolated syndromes suggestive of multiple sclerosis,part Ⅰ:natural history,pathogenesis,diagnosis,and prognosis显示文摘 | Miller D Barkhof F Montalban X | | 0，，： | 1 |
| 6 | MRI criteria for MS in patients with clinically isolated syndromes显示文摘 | Montalban X TintoréM Swanton JK | 2010 | Neurology2010，74，5： | 1 |
| 7 | APS and the brain显示文摘 | Sastre-Garriga J Montalban X | 2003 | Lupus2003，12，： | 1 |
| 8 | FTY-720(fingolimod) for relapsing multiple sclerosis 显示文摘 | HORGA A MONTALBAN X | 2008 | Expert Rev Neurother2008，8，5： | 1 |
| 9 | FTY720 (fingolimod) for relapsing multiple sclerosis显示文摘 | Horga A Montalban X | | 0，，05： | 1 |
| 10 | The value of animal models for drug development in multiple sclerosis 显示文摘 | Friese M A Montalban X Willcox N | 2006 | Brain2006，129，8： | 1 |
| 11 | Daclizumab in active relapsing muhiple sclerosis ( CHOICE study) : a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta显示文摘 | Wynn D Kaufman M Montalban X | 2010 | Lancet Neurol2010，9，4： | 1 |
| 12 | Clinically isolated syndromes suggestive of multiple sclerosis,part Ⅰ:natural history,pathogenesis,diagnosis,and prognosis显示文摘 | Miller D Barkhof F Montalban X | 2005 | Lancet Neurol2005，，： | 1 |
| 13 | Clinically isolated syndromes suggestive of multiple sclerosis,part I:natural history,pathogenesis,diagnosis and prognosis显示文摘 | Miller D Barkhof F Montalban X | | 0，，： | 1 |
| 14 | Phase Ⅱ study of oral fingolimod (FTY720) in multiple sclerosis:3-year results显示文摘 | Comi G O'connor P Montalban X | | 0，，02： | 1 |
| 15 | Semaphorins 3A and 7A:potential immune and neuroregenerative targets in multiple sclerosis显示文摘 | Eixarch H Gutiérrez-Franco A Montalban X | | 0，，03： | 1 |
| 16 | Antimyelin anti-bodies with no progression to multiple sclerosis 显示文摘 | Pelayo R Tintore M Montalban X | 2007 | NewEngl J Med2007，356，： | 1 |
| 17 | Tumor necros- is factor alpha (TNF-c0, anti-TNF-ct and demyelination revisited: an ongoing story 显示文摘 | Caminero A Comabella M Montalban X | 2011 | Journal of Neuroimmuno- logy2011，234，12： | 1 |
| 18 | Antibodies against gangluosides in patients with SLE and neuological manifestations显示文摘 | Tintore M Montalban J | 1992 | Lupus1992，1，5： | 1 |
| 19 | Targeting dendritic cells to treat multiple sclerosis 显示文摘 | Comabella M Montalban X Miinz C | 2010 | Nat Rev Neurol2010，6，9： | 1 |
| 20 | Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta 显示文摘 | Wynn D Kaufman M Montalban X | 2010 | LancetNeurol2010，9，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员